NCT06403709View on ClinicalTrials.gov

Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2026

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab

These patients received an intravenous infusion of irinotecan (150mg/m2 on day 1) plus bevacizumab (5 mg/kg on day 1) and an oral administration of TAS-102(30 mg/m2 given bid on days 1-5), repeated every 14 days.

Trial Locations (1)

Unknown

Beijing Chaoyang Sanhuan Cancer Hospital, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER